Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations

What happened

Perrigo reported third-quarter 2026 financial results from continuing operations for the period ended September 26. It said its Three-S plan was supporting sequential improvement in operating results and market share gains in U.S. store-brand over-the-counter products and key European brands. The company expects the Infant Formula sale to simplify its portfolio.

Confirmed

Global impact / market context

A completed Infant Formula sale would leave Perrigo more focused on consumer self-care products. Management expects it to lower future capital spending and support repayment of borrowed money and reinvestment, while the updated outlook also reflects retailer inventory caution and continued weakness in Europe.

Analyst inference

The update combines reported progress in U.S. store-brand over-the-counter products and selected European brands with a cautious outlook. More measured retailer inventory positioning means retailers are managing stock carefully, which can limit orders to suppliers; continued European softness may also constrain sales growth.

Analyst inference

What to watch

1. Watch for completion and financial details of the Infant Formula divestiture, including whether the expected reduction in future capital spending and support for debt repayment are realized. Analyst inference
2. Perrigo says its full-year 2026 outlook was updated for the divestiture, cautious retailer inventory positioning, and continued European softness; the supplied text gives no forecast figures. Confirmed
3. The strategic review of Oral Care remains ongoing; any resulting decision could change Perrigo’s product focus, spending needs, or sources of sales. Confirmed

Evidence

• Original source link unavailable